Zobrazeno 1 - 10
of 16
pro vyhledávání: '"L. Edward Clemens"'
Publikováno v:
Frontiers in Microbiology, Vol 10 (2019)
The relentless growth of multidrug resistance and generation of recalcitrant biofilm are major obstacles in treating wounds, particularly in austere military environments where broad-spectrum pathogen coverage is needed. Designed antimicrobial peptid
Externí odkaz:
https://doaj.org/article/12cc5f86d5064d8e99488018b6a67ad3
Publikováno v:
Journal of Fungi, Vol 6, Iss 3, p 184 (2020)
Cutaneous invasive fungal wound infections after life-threatening dismounted complex blast injury (DCBI) and natural disasters complicate clinical care. These wounds often require aggressive repeated surgical debridement, can result in amputations an
Externí odkaz:
https://doaj.org/article/e27a9be06ada4a478ad52c90b0ec5247
Publikováno v:
Antibiotics, Vol 9, Iss 1, p 23 (2020)
Acne vulgaris, caused by the Gram-positive bacterium Cutibacterium acnes, is a prevalent dermatologic condition with substantial cutaneous and psychological morbidity. Mild acne is treated with topical antibiotics with more severe inflammatory forms
Externí odkaz:
https://doaj.org/article/b176a828ff68422195edb0c5f0305e71
Autor:
Apurva Chandalia, Holly J. Clarke, L. Edward Clemens, Bindu Pandey, Vic Vicena, Paul Lee, Brian E. Lavan, Francine M. Gregoire
Publikováno v:
PPAR Research, Vol 2009 (2009)
MBX-102/JNJ-39659100 (MBX-102) is a selective, partial PPAR-𝛾 agonist that lowers glucose in the absence of some of the side effects, such as weight gain and edema, that are observed with the TZDs. Interestingly MBX-102 also displays pronounced tr
Externí odkaz:
https://doaj.org/article/31e2dabb7bc34b4c853837fb6a301713
Publikováno v:
Frontiers in Microbiology
Frontiers in Microbiology, Vol 10 (2019)
Frontiers in Microbiology, Vol 10 (2019)
The relentless growth of multidrug resistance and generation of recalcitrant biofilm are major obstacles in treating wounds, particularly in austere military environments where broad-spectrum pathogen coverage is needed. Designed antimicrobial peptid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28482f01b495969a27fe968e2340e7ea
https://pubmed.ncbi.nlm.nih.gov/31396193
https://pubmed.ncbi.nlm.nih.gov/31396193
Publikováno v:
Cosmetic Formulation ISBN: 9780429190674
Cosmetic Formulation
Cosmetic Formulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b2569fe486dfea4658254047871cebf
https://doi.org/10.1201/9780429190674-15
https://doi.org/10.1201/9780429190674-15
Autor:
Lydia-Marie Joubert, Hasan Nazik, Alfred Botha, David A. Stevens, Jesse M. Jaynes, L. Edward Clemens, Kathryn W Woodburn
Publikováno v:
Antimicrobial Agents and Chemotherapy
Recurrent vulvovaginal candidiasis (RVVC) is a widespread chronic infection that has a substantial negative impact on work and quality of life. The development of antimicrobial resistance and biofilm formation are speculated to contribute to Candida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea199438ce05a79ee0f7b5ad22ac2583
https://pubmed.ncbi.nlm.nih.gov/31451496
https://pubmed.ncbi.nlm.nih.gov/31451496
Publikováno v:
Antibiotics
Volume 9
Issue 1
Antibiotics, Vol 9, Iss 1, p 23 (2020)
Volume 9
Issue 1
Antibiotics, Vol 9, Iss 1, p 23 (2020)
Acne vulgaris, caused by the Gram-positive bacterium Cutibacterium acnes, is a prevalent dermatologic condition with substantial cutaneous and psychological morbidity. Mild acne is treated with topical antibiotics with more severe inflammatory forms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4e427c8858bf8b37011b6f3a17809da
https://doi.org/10.3390/antibiotics9010023
https://doi.org/10.3390/antibiotics9010023
Autor:
Alison M. McDermott, Kathryn W Woodburn, Hasna Baidouri, L. Edward Clemens, Jesse M. Jaynes, Rose Y. Reins, Satya Sree N. Kolar, Edward Lim, Samuel D Hanlon
Publikováno v:
Investigative Ophthalmology & Visual Science
Purpose: To limit corneal damage and potential loss of vision, bacterial keratitis must be treated aggressively. Innovation in antimicrobials is required due to the need for empirical treatment and the rapid emergence of bacterial resistance. Designe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2069cdc291239633dc3c7dbe051f4e74
https://nrl.northumbria.ac.uk/id/eprint/33165/1/i1552-5783-58-14-6273.pdf
https://nrl.northumbria.ac.uk/id/eprint/33165/1/i1552-5783-58-14-6273.pdf
Autor:
Fang Zhang, Dennis Rentzeperis, Francine M. Gregoire, Holly J. Clarke, Brian Edward Lavan, Thomas A. Gustafson, Svetlana Favelyukis, Dorothy D. Sears, L. Edward Clemens, James M. Lenhard, Yi Mu
Publikováno v:
Molecular Endocrinology. 23:975-988
MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d5a0582832e3857944e294f2920342f
https://doi.org/10.1210/me.2008-0473
https://doi.org/10.1210/me.2008-0473